HUP0203836A2 - 1,3-Diszubsztituált pirrolidin-származékok alfa2-adrenerg-receptor antagonista hatással, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
1,3-Diszubsztituált pirrolidin-származékok alfa2-adrenerg-receptor antagonista hatással, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0203836A2 HUP0203836A2 HU0203836A HUP0203836A HUP0203836A2 HU P0203836 A2 HUP0203836 A2 HU P0203836A2 HU 0203836 A HU0203836 A HU 0203836A HU P0203836 A HUP0203836 A HU P0203836A HU P0203836 A2 HUP0203836 A2 HU P0203836A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkyl
- hydrogen
- halogen atom
- atom
- Prior art date
Links
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title 1
- 102000015006 alpha2-adrenergic receptor activity proteins Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- -1 methylenedioxy group Chemical group 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
A találmány (I) általános képletű vegyületekre vonatkozik szabad bázisvagy savadíciós só formájában ebben a képletben R0 jelentésehidrogénatom vagy alkilcsoport. R1 jelentése alkoxicsoport vagyalkenilcsoport, és jelenthet halogénatomot, hidroxilcsoportot,alkilcsoportot, trifluor-metilcsoportot vagy trifluor-metoxicsoportotis, R2 hidrogénatom, halogénatom, hidroxilcsoport, alkilcsoport,alkoxicsoport, 2-5-trifluor-metil- vagy trifluor-metoxicsoport, vagyha R1-hez képest orto helyzetben van, akkor R1 és R2 együtt metilén-dioxicsoportot alkothat és A tetrahidropirán-4-il-csoport vagy egy(a), (b), (c), (d), (e), (f), vagy (g) képletű csoport, ahol m értéke1-3 X oxigén- vagy kénatom, vagy -CH=CH-csoport, R3 hidrogén- vagyhalogénatom, hidroxilcsoport, alkilcsoport, hidroxi-alkilcsoport,alkoxicsoport, trifluor-metilcsoport, alkil-szulfonil-aminocsoport,benzil-oxicsoport, karbamoilcsoport, alkil-karbamoilcsoport vagydi(alkil)-karbamoilcsoport; R4 és R5 hidrogén- vagy halogénatom,alkil- vagy alkoxicsoport; R6 hidrogén- vagy halogénatom vagyalkilcsoport, R7 hidrogénatom, vagy alkilcsoport vagy cikloalkil-(1-4szénatomos alkilcsoport), vagy R8 hidrogén- vagy halogénatom,hidroxilcsoport, alkilcsoport, alkoxicsoport, adott esetbenhelyettesített aminocsoport, és R9 hidrogén- vagy halogénatom,alkilcsoport vagy fenilcsoport, vagy R8 és R9 együtt -O-(CH2)m O-képletű csoport, ahol m a fenti jelentésű, R10 hidrogénatom,alkilcsoport cikloalkil-alkilcsoport alkil-karbonilcsoport,cikloalkil-karbonilcsoport, alkoxi-karbonilcsoport, benzilcsoport,benziloxi-karbonilcsoport, benzoilcsoport, helyettesített szulfonilvagy aminocsoport. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0002100.6A GB0002100D0 (en) | 2000-01-28 | 2000-01-28 | Organic compounds |
PCT/EP2001/000861 WO2001055132A1 (en) | 2000-01-28 | 2001-01-26 | 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0203836A2 true HUP0203836A2 (hu) | 2003-03-28 |
HUP0203836A3 HUP0203836A3 (en) | 2005-03-29 |
Family
ID=9884609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203836A HUP0203836A3 (en) | 2000-01-28 | 2001-01-26 | 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use |
Country Status (28)
Country | Link |
---|---|
US (1) | US7012085B2 (hu) |
EP (1) | EP1257547B1 (hu) |
JP (1) | JP2003523353A (hu) |
KR (1) | KR20020069375A (hu) |
CN (2) | CN1305847C (hu) |
AR (1) | AR029463A1 (hu) |
AT (1) | ATE384715T1 (hu) |
AU (1) | AU768844B2 (hu) |
BR (1) | BR0107888A (hu) |
CA (1) | CA2398794C (hu) |
CO (1) | CO5261521A1 (hu) |
CZ (1) | CZ20022581A3 (hu) |
DE (1) | DE60132558T2 (hu) |
ES (1) | ES2296763T3 (hu) |
GB (1) | GB0002100D0 (hu) |
HU (1) | HUP0203836A3 (hu) |
IL (1) | IL150550A0 (hu) |
MX (1) | MXPA02007318A (hu) |
MY (1) | MY128639A (hu) |
NO (1) | NO20023485L (hu) |
NZ (1) | NZ520342A (hu) |
PE (1) | PE20011068A1 (hu) |
PL (1) | PL202473B1 (hu) |
PT (1) | PT1257547E (hu) |
RU (1) | RU2002121646A (hu) |
SK (1) | SK10802002A3 (hu) |
WO (1) | WO2001055132A1 (hu) |
ZA (1) | ZA200205991B (hu) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0002100D0 (en) * | 2000-01-28 | 2000-03-22 | Novartis Ag | Organic compounds |
US6436972B1 (en) | 2000-04-10 | 2002-08-20 | Dalhousie University | Pyridones and their use as modulators of serine hydrolase enzymes |
AU2003216954A1 (en) * | 2002-03-29 | 2003-10-13 | Orion Corporation | Treatment of dependence and dependence related withdrawal symptoms |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
JP2008037850A (ja) * | 2006-08-10 | 2008-02-21 | Mitsubishi Tanabe Pharma Corp | 新規置換ピペリジン誘導体 |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
BRPI0816767B8 (pt) | 2007-09-14 | 2021-05-25 | Addex Pharmaceuticals Sa | composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
AU2009289784B2 (en) | 2008-09-02 | 2012-03-22 | Addex Pharma S.A. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
MY161325A (en) | 2009-05-12 | 2017-04-14 | Janssen Pharmaceuticals Inc | 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US8946205B2 (en) | 2009-05-12 | 2015-02-03 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
AU2011328203B2 (en) | 2010-11-08 | 2015-03-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
CN103261195B (zh) | 2010-11-08 | 2015-09-02 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
GB2503187A (en) * | 2011-09-15 | 2013-12-25 | Univ Sussex | Composition for use in the treatment of neurodevelopmental disorders |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
EP2935253B1 (en) | 2012-12-21 | 2018-08-01 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
ES2806135T3 (es) | 2013-06-21 | 2021-02-16 | Zenith Epigenetics Ltd | Nuevos inhibidores de bromodominios bicíclicos |
JP6599852B2 (ja) | 2013-06-21 | 2019-10-30 | ゼニス・エピジェネティクス・リミテッド | ブロモドメイン阻害剤としての新規の置換された二環式化合物 |
CN105593224B (zh) | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
KR102461134B1 (ko) | 2014-01-21 | 2022-10-28 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
UA121965C2 (uk) | 2014-01-21 | 2020-08-25 | Янссен Фармацевтика Нв | Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування |
CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
JP2017537946A (ja) | 2014-12-11 | 2017-12-21 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | ブロモドメイン阻害剤としての置換複素環 |
CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US5185364A (en) | 1988-01-15 | 1993-02-09 | Abbott Laboratories | Aminomethyl-chroman and -thiochroman compounds |
AU653837B2 (en) * | 1991-04-17 | 1994-10-13 | Pharmacia & Upjohn Company | Substituted phenylazacycloalkanes as CNS agents |
GB9113031D0 (en) | 1991-06-17 | 1991-08-07 | Smithkline Beecham Plc | Compounds |
FR2687146B1 (fr) * | 1992-02-12 | 1994-04-01 | Adir Cie | Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
ATE243196T1 (de) | 1994-03-09 | 2003-07-15 | Novo Nordisk As | Piperidine und pyrrolidine |
SE9802546D0 (sv) | 1998-07-15 | 1998-07-15 | Ross Nicholas Waters | Medicinal product and method for treatment and prevention of dyskinesia |
IT1303737B1 (it) | 1998-11-11 | 2001-02-23 | Smithkline Beecham Spa | Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1. |
GB0002100D0 (en) * | 2000-01-28 | 2000-03-22 | Novartis Ag | Organic compounds |
-
2000
- 2000-01-28 GB GBGB0002100.6A patent/GB0002100D0/en not_active Ceased
-
2001
- 2001-01-23 MY MYPI20010309A patent/MY128639A/en unknown
- 2001-01-25 AR ARP010100318A patent/AR029463A1/es unknown
- 2001-01-26 JP JP2001560991A patent/JP2003523353A/ja active Pending
- 2001-01-26 MX MXPA02007318A patent/MXPA02007318A/es active IP Right Grant
- 2001-01-26 PL PL356265A patent/PL202473B1/pl not_active IP Right Cessation
- 2001-01-26 AT AT01946858T patent/ATE384715T1/de not_active IP Right Cessation
- 2001-01-26 AU AU28501/01A patent/AU768844B2/en not_active Ceased
- 2001-01-26 CA CA002398794A patent/CA2398794C/en not_active Expired - Fee Related
- 2001-01-26 CZ CZ20022581A patent/CZ20022581A3/cs unknown
- 2001-01-26 EP EP01946858A patent/EP1257547B1/en not_active Expired - Lifetime
- 2001-01-26 IL IL15055001A patent/IL150550A0/xx unknown
- 2001-01-26 WO PCT/EP2001/000861 patent/WO2001055132A1/en active IP Right Grant
- 2001-01-26 KR KR1020027009705A patent/KR20020069375A/ko not_active Application Discontinuation
- 2001-01-26 US US10/182,090 patent/US7012085B2/en not_active Expired - Fee Related
- 2001-01-26 PE PE2001000086A patent/PE20011068A1/es not_active Application Discontinuation
- 2001-01-26 ES ES01946858T patent/ES2296763T3/es not_active Expired - Lifetime
- 2001-01-26 CN CNB2004100839164A patent/CN1305847C/zh not_active Expired - Fee Related
- 2001-01-26 SK SK1080-2002A patent/SK10802002A3/sk unknown
- 2001-01-26 NZ NZ520342A patent/NZ520342A/en unknown
- 2001-01-26 PT PT01946858T patent/PT1257547E/pt unknown
- 2001-01-26 HU HU0203836A patent/HUP0203836A3/hu unknown
- 2001-01-26 CN CNB018042341A patent/CN1178935C/zh not_active Expired - Fee Related
- 2001-01-26 RU RU2002121646/04A patent/RU2002121646A/ru not_active Application Discontinuation
- 2001-01-26 BR BR0107888-7A patent/BR0107888A/pt not_active Application Discontinuation
- 2001-01-26 DE DE60132558T patent/DE60132558T2/de not_active Expired - Fee Related
- 2001-01-29 CO CO01006310A patent/CO5261521A1/es not_active Application Discontinuation
-
2002
- 2002-07-22 NO NO20023485A patent/NO20023485L/no not_active Application Discontinuation
- 2002-07-26 ZA ZA200205991A patent/ZA200205991B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0203836A2 (hu) | 1,3-Diszubsztituált pirrolidin-származékok alfa2-adrenerg-receptor antagonista hatással, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0300894A2 (hu) | Szubsztituált béta-karbolinok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0204235A2 (hu) | Helyettesített glutárimidek és felhasználásuk IL-12 termelés inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0104768A2 (hu) | 4-Amino-3-oxo-azepán proteáz inhibitorok és az ezeket tartalmazó gyógyszerkészítmények | |
PT1263724E (pt) | Novos compostos | |
HUP0300693A2 (hu) | Eljárás epotilon-analógok és -intermedierek előállítására | |
NO20080456L (no) | Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer | |
HUP0401777A2 (hu) | 3H-[1,2,4]Triazolo[5,1-i]purin-5-il-aminok mint adenozin A2a receptor antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0301187A2 (hu) | Új benzil-piperidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
HUP0300068A2 (en) | Protease inhibitors, their preparation, their use and pharmaceutical compositions containing them | |
NO20025821L (no) | 2-aminokarbonyl-9H-purinderivater | |
HUP0500610A2 (hu) | Indazol-, benzotiazol- és benzoizotiazol-származékok, ezeket tartalmazó gyógyszerkészítmények és ezek alkalmazása | |
NO974734L (no) | Nye arylglycinamidderivater, fremgangsmåte for deres fremstilling og farmasaöytiske blandinger inneholdende disse forbindelser | |
SE0301446D0 (sv) | New Compounds | |
HUP0500034A2 (hu) | N-Aril-N'-(aril-cikloalkil)-karbamid-származékok mint MCH antagonisták és ezeket hatóanyagként tartalmazó gyógyszerkészítmények | |
SE0403171D0 (sv) | New compounds | |
NO20040589L (no) | Arylsulfonylderivater med 5-HT6 reseptor affinitet. | |
HUP0302115A2 (hu) | Tiazabiciklo[3.2.2]nonán-fenil-izoxazol-származékok, előállításuk és ezeket tartalamzó gyógyszerkészítmények | |
HUP0302193A2 (hu) | 1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP0204394A2 (en) | Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same | |
ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
DE60322064D1 (de) | 4,4' -dithiobis- (3-aminobutane-1-sulfonate)-derivate und sie enthaltende zusammensetzungen | |
HUP0401563A2 (hu) | Új piperidinarboxamid-származékok, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
NO961077L (no) | Substituerte benzoltienylpiperaziner, deres anvendelse som medikamenter og fremgangsmåter for fremstilling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |